Juno shelves JCAR015, shifts focus to earlier compound

Following major setbacks for its lead candidate, the CAR-T company is pumping additional resources into another one of its main cancer immunotherapies, JCAR017.

By Jacob Bell • March 1, 2017

Kite flying high on Zuma-1 data

The CAR-T specialist plans to fully submit its lead candidate for approval after Phase 2 data showed the drug effectively treated patients with non-Hodgkin lymphoma.

By Jacob Bell • Feb. 28, 2017

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

By BioPharma Dive staff

Merck antiviral cuts post-transplant infections

The big pharma readies an NDA submission after reducing CMV infection and boosting survival in bone marrow transplant patients.

By Suzanne Elvidge • Feb. 28, 2017

Industry Pulse: Who's spending on R&D?

As top-selling drugs age, biopharma continues to hunt for ever-elusive innovation. Here are eight charts explaining which pharmas need it most, and which are turning to internal R&D to capture it. 

By Ned Pagliarulo • Feb. 28, 2017

La Jolla surges on Phase 3 results for shock patients

The San Diego-based company says its synthetic formulation of a blood-pressure regulator offers a new level of treatment for shock patients who fail first- and second-line therapies in the ICU.

By Judy Packer-Tursman • Feb. 27, 2017

Bristol, Roche team up with Exelixis on cancer trials

The California-based biotech will test its drug, cabozantinib, in combination with Roche's Tecentriq and Bristol-Myers Squibb's Opdivo.

By Jacob Bell • Feb. 27, 2017

Cempra touting positive antibiotic results

A bit of good news for anti-infectives company after a difficult close to 2016.

By Suzanne Elvidge • Feb. 27, 2017

Prescribed Reading: Bristol M&A steals the show

Debate about the future of Bristol-Myers dominated news coverage this week, while several cancer drugs failed in late-stage trials. 

By Lisa LaMotta • Feb. 24, 2017

Merck writes off $2.9B as new hep C reality blooms

The accounting charge will drag down 2016 earnings per share and reflects shifting market and pricing dynamics, the drugmaker said. 

By Ned Pagliarulo • Feb. 24, 2017

Aveo's tivozanib finally moving forward after 4-year delay

The biotech's study provides data for the company's second go at approval.

By Suzanne Elvidge • Feb. 24, 2017

Resverlogix gets FDA input, redesigns kidney trial

This is the Canadian biotech’s third announcement over the past month on studies related to the potential of its lead candidate, apabetalone.

By Judy Packer-Tursman • Feb. 24, 2017

Cyclacel's lead candidate flops in Phase 3

The clinical-stage company's stock fell more than 20% on news that its cancer medication didn't improve overall survival in elderly patients with leukemia.

By Jacob Bell • Feb. 23, 2017

Safety concerns reemerge for Roche hemophilia drug

Roche hopes to file for approval of emicizumab in certain hemophilia A patients this year, but a patient death reported this week refocuses attention on the drug's safety profile. 

By Ned Pagliarulo • Feb. 23, 2017

Bayer touts Xarelto strength on heels of COMPASS data

The blood thinner led the German company’s pharma growth last year, but Eylea, cancer drugs and a pulmonary hypertension treatment also played key roles.

By Judy Packer-Tursman • Feb. 23, 2017

DMC: little promise for Argos cancer therapy

Argos stock plummeted more than 66% on news that an independent data monitoring committee recommended stopping a Phase 3 study of its cancer drug.

By Jacob Bell • Feb. 22, 2017

Pfizer, Celltrion pushing for interchangeability with Inflectra

Positive data could support a claim of interchangeability for the biosimilar of Remicade. 

By Jacob Bell • Feb. 22, 2017

Trevena stock tanks despite positive late-stage results

The clinical-stage company's lead candidate outperformed placebo, but analysts questioned whether the pain medication's safety profile would get it to market.

By Jacob Bell • Feb. 21, 2017

Capricor scraps heart-failure drug to focus on cell, exosome therapies

The Los Angeles-based biotech is shifting gears to push forward with a cardiac cell therapy. 

By Judy Packer-Tursman • Feb. 20, 2017

Celgene notches clinical victory for its first MS drug

The highly anticipated drug, ozanimod, outperformed Biogen's Avonex in treating patients with relapsing multiple sclerosis.

By Jacob Bell • Feb. 17, 2017

Pfizer's Xeljanz falls short in match-up with Humira

Xeljanz monotherapy failed to beat out a combination of Humira and methotrexate, crimping hopes the JAK inhibitor could stand on its own in the competitive class. 

By Judy Packer-Tursman • Feb. 17, 2017

Daiichi, ArQule cancer drug fails in late-stage study

The companies have struggled to get the drug, tivantinib, through Phase 3 testing for different types of cancers, including liver and lung.

By Jacob Bell • Feb. 17, 2017

Prescribed Reading: Sage CEO embellishes, Merck stumbles

Plus, Valeant gets an approval, but is still in a tight spot; Allergan continues its deal spree; and PhRMA tries to deal with image issues. 

By Lisa LaMotta • Feb. 17, 2017

Alexion shutters further development of rare disease candidate

The rare disease drugmaker remains heavily dependent on sales of its main drug Soliris, and questions still linger from management turnover late last year. 

By Suzanne Elvidge • Feb. 17, 2017

Takeda, PRA expand R&D partnership into Japan

Less than half a year after first pairing up, the two companies are creating a new joint venture to support Takeda's drug development work in its home base. 

By Suzanne Elvidge • Feb. 16, 2017

Ardelyx asserts kidney drug is back on track

Despite positive trial data, skepticism remains for Ardelyx's tenapanor after previous trial failures, safety concerns and partners backing away. 

By Judy Packer-Tursman • Feb. 16, 2017